drugset
drugset / Trial / NCT04349761

Single Ascending-dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male Adult Subjects

NCT04349761 ↗

Phase 1 Completed 40 enrolled TNF Pharmaceuticals, Inc.
RandomizedParallel-groupDouble-blindOther

Summary

Double-blind, placebo-controlled, First-in-Human, single ascending-dose study. Approximately 40 healthy adult male subjects will be given a single capsule of MYMD1 to determine its safety, how well it is tolerated, how the body acts on the experimental drug, and how the experimental drug acts on the body. This will be based on blood and urine sample analysis and other physical measurements.

Timeline

Start
2019-06-11
Primary completion
2019-12-30
Completion
2019-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject ISOMIOSAMINE Small molecule 5 mg Oral
Subject ISOMIOSAMINE Small molecule 10 mg Oral
Subject ISOMIOSAMINE Small molecule 15 mg Oral
Subject ISOMIOSAMINE Small molecule 20 mg Oral
Subject ISOMIOSAMINE Small molecule 25 mg Oral

Indications

No indication recorded.